Table 1.
ARID1a expression | BRG1 expression | BRM expression | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Negative | Positive | p-value | Negative | Positive | p-value | Negative | Positive | p-value | ||||||||||
Total | 560* | 58 | 10.4% | 502 | 89.6% | 563* | 19 | 3.4% | 544 | 96.6% | 578* | 57 | 9.9% | 521 | 90.1% | |||
Sex | ||||||||||||||||||
Female | 65 | 7 | 10.8% | 58 | 89.2% | 0.831 | 67 | 1 | 1.5% | 66 | 98.5% | 0.715 | 68 | 11 | 16.2% | 57 | 83.8% | 0.080 |
Male | 495 | 51 | 10.3% | 444 | 89.7% | 496 | 18 | 3.6% | 478 | 96.4% | 510 | 46 | 9.0% | 464 | 91.0% | |||
Age group | ||||||||||||||||||
<65 | 185 | 17 | 9.2% | 168 | 90.8% | 0.399 | 186 | 4 | 2.2% | 182 | 97.8% | 0.239 | 191 | 20 | 10.5% | 171 | 89.5% | 0.199 |
>65 | 174 | 19 | 10.9% | 155 | 89.1% | 170 | 9 | 5.3% | 161 | 94.7% | 173 | 20 | 11.6% | 153 | 88.4% | |||
pT stage | ||||||||||||||||||
1 | 81 | 9 | 11.1% | 72 | 88.9% | 0.657 | 79 | 3 | 3.8% | 76 | 96.2% | 0.448 | 86 | 8 | 9.3% | 78 | 90.7% | 0.981 |
2 | 72 | 8 | 11.1% | 64 | 88.9% | 73 | 1 | 1.4% | 72 | 98.6% | 72 | 6 | 8.3% | 66 | 91.7% | |||
3 | 385 | 41 | 10.6% | 344 | 89.4% | 388 | 13 | 3.4% | 375 | 96.6% | 398 | 41 | 10.3% | 357 | 89.7% | |||
4 | 19 | 0 | 0% | 19 | 100% | 20 | 2 | 10% | 18 | 90.0% | 20 | 2 | 10.0% | 18 | 90.0% | |||
Lymph node metastasis | ||||||||||||||||||
pN0 | 217 | 31 | 14.3% | 186 | 85.7% | 0.086 | 216 | 8 | 3.7% | 208 | 96.3% | 0.952 | 227 | 20 | 8.8% | 207 | 91.2% | 0.651 |
pN 1 | 196 | 13 | 6.6% | 183 | 93.4% | 197 | 6 | 3% | 191 | 97.0% | 194 | 23 | 11.9% | 171 | 88.1% | |||
pN 2 | 74 | 7 | 9.5% | 67 | 90.5% | 74 | 2 | 2.7% | 72 | 97.3% | 79 | 6 | 7.6% | 73 | 92.4% | |||
pN 3 | 71 | 7 | 9.9% | 64 | 90.1% | 74 | 3 | 4.1% | 71 | 95.9% | 76 | 8 | 10.5% | 68 | 89.5% | |||
Grading | ||||||||||||||||||
G1 | 4 | 1 | 25% | 3 | 75% | 0.186 | 5 | 0 | 0% | 5 | 100% | < 0.001 | 6 | 0 | 0% | 6 | 100% | 0.119 |
G2 | 218 | 16 | 7.3% | 202 | 92.7% | 217 | 3 | 1.4% | 214 | 98.6% | 221 | 20 | 9.0% | 201 | 91.0% | |||
G3 | 167 | 22 | 13.2% | 145 | 86,8% | 172 | 10 | 5.8% | 162 | 94.2% | 177 | 24 | 13.6% | 153 | 86.4% |
*Total numbers of patients do not add due to missing clinical data in some cases